Novel Cuproptosis-Related Gene Signature for Precise Identification of High-Risk Populations in Low-Grade Gliomas

Table 1

Clinical characteristic of the LGG patient used in this study.

	TCGA		CGGA		Total
	Low immune score ()	High immune score ()	Low immune score ()	High immune score ()	Low immune score ()	High immune score ()
Sex
Female	196 (44.7%)	31 (45.6%)	151 (43.9%)	34 (44.7%)	347 (44.4%)	65 (45.1%)
Male	242 (55.3%)	37 (54.4%)	193 (56.1%)	42 (55.3%)	435 (55.6%)	79 (54.9%)
Age (years)
Median [min, max]	41.0 [14.0, 87.0]	44.0 [22.0, 75.0]	40.0 [12.0, 69.0]	40.0 [11.0, 72.0]	41.0 [12.0, 87.0]	41.0 [11.0, 75.0]
Status
Alive	341 (77.9%)	39 (57.4%)	193 (56.1%)	30 (39.5%)	534 (68.3%)	69 (47.9%)
Dead	97 (22.1%)	29 (42.6%)	151 (43.9%)	46 (60.5%)	248 (31.7%)	75 (52.1%)
Grade
II	232 (53.0%)	14 (20.6%)	144 (41.9%)	28 (36.8%)	376 (48.1%)	42 (29.2%)
Ill	206 (47.0%)	54 (79.4%)	200 (58.1%)	48 (63.2%)	406 (51.9%)	102 (70.8%)
Follow-up time (months)
^Median [min, max]	22.3 [0.0300, 211]	21.5 [0.100, 105]	50.6 ^[1.70, 158]	33.3 ^[2.23, 168]	31.2 ^[0.0300, 211]	^26.6 [0.^100, 168]